Synopsis :

Dr Reddy’s Laboratories shares fell 6% after receiving a non-compliance notice from Canada’s drug regulator for its Semaglutide injection, raising concerns of delayed approval, loss of first-mover advantage, and potential revenue impact in FY26–FY27.

This company is a leading India-based pharmaceutical company which offers a portfolio of products and services is now in the spotlight after it received a non compliance notice from Canada’s drug regulator for its injection.

With market capitalization of Rs. 1,00,529 cr, the shares of Dr Reddy’s Laboratories Ltd are currently trading at Rs. 1,207 per share, down by 6% in today’s market session making a low of Rs. 1,180.90, from its previous close of Rs. 1,250.90 per share.

News

Shares of Dr Reddy’s Laboratories fell nearly

See Full Page